Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Total Liabilities (2016 - 2025)

Medifast's Total Liabilities history spans 16 years, with the latest figure at $49.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 33.81% year-over-year to $49.1 million; the TTM value through Dec 2025 reached $49.1 million, down 33.81%, while the annual FY2025 figure was $49.1 million, 33.81% down from the prior year.
  • Total Liabilities reached $49.1 million in Q4 2025 per MED's latest filing, down from $53.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $211.1 million in Q2 2022 to a low of $49.1 million in Q4 2025.
  • Average Total Liabilities over 5 years is $126.4 million, with a median of $130.1 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: skyrocketed 65.77% in 2021, then crashed 39.57% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $195.9 million in 2021, then decreased by 17.71% to $161.2 million in 2022, then tumbled by 32.72% to $108.4 million in 2023, then crashed by 31.66% to $74.1 million in 2024, then plummeted by 33.81% to $49.1 million in 2025.
  • Per Business Quant, the three most recent readings for MED's Total Liabilities are $49.1 million (Q4 2025), $53.5 million (Q3 2025), and $53.3 million (Q2 2025).